Press Releases
Chimeron Bio’s COVID-19 Vaccine Demonstrates Positive Pre-Clinical Results
Chimeron Bio and George Mason University’s National Center for Biodefense and Infectious Diseases Partner to Develop a Coronavirus (COVID-19) Vaccine using ChaESAR™ Technology
Chimeron Bio Appoints Eminent Virologist Dr. Jonathan Smith to its Scientific Advisory Board as it Initiates COVID-19 Vaccine Program
A Message from the CEO on the COVID-19 Initiative
Chimeron Bio Launches Vaccine Program for COVID-19
Chimeron Bio Announces Appointment of Dr. Dominique Gouty to its Scientific Advisory Board
Chimeron Bio Announces Appointment of Dr. Robert (Bob) Willette to its Scientific Advisory Board
Chimeron Bio Announces Appointment of Dr. Afshin Safavi to Chairman of the Board
Media Inquiries
Interested in learning more about Chimeron Bio’s novel technology and the work we are doing to develop first-in-class self-amplifying RNA therapeutics?
Reach out to us at contact@chimeronbio.com today.
Follow Us
Harnessing the Power of saRNA with ChaESAR
Chimeron Bio’s ChaESAR platform is enabling application of saRNA biology to treat multiple genetic disorders and diseases.